Ptc Therapeutics (PTCT) Accumulated Expenses (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Accumulated Expenses of $39.3 million for Q2 2026, up 2.76% year-over-year from $38.2 million in Q2 2025, and up 16.13% quarter-over-quarter from $33.8 million in Q1 2026.
Ptc Therapeutics (PTCT) Accumulated Expenses (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $39.3 million for Q2 2026.
- In Q2 2026, Accumulated Expenses rose 2.76% year-over-year to $39.3 million; the TTM figure through Jun 2026 stood at $39.3 million (up 2.76% YoY), while the FY2025 annual figure was $73.7 million, up 19.75% from the prior year.
- Accumulated Expenses for Q2 2026 stood at $39.3 million, up from $33.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $73.7 million in Q4 2025, with the low at $29.5 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $42.8 million (2024), against an average of $46.6 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 52.63% in 2023, then plunged 34.71% in 2024.
- Ptc Therapeutics' Accumulated Expenses stood at $62.7 million in 2022, then decreased by 0.04% to $62.6 million in 2023, then decreased by 1.7% to $61.6 million in 2024, then rose by 19.75% to $73.7 million in 2025, then slumped by 46.7% to $39.3 million in 2026.
- Business Quant data shows PTCT's Accumulated Expenses at $39.3 million in Q2 2026, $33.8 million in Q1 2026, and $73.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.30 Mn |
| Mar 31, 2026 | 33.84 Mn |
| Dec 31, 2025 | 73.74 Mn |
| Sep 30, 2025 | 49.47 Mn |
| Jun 30, 2025 | 38.25 Mn |
| Mar 31, 2025 | 32.09 Mn |
| Dec 31, 2024 | 61.58 Mn |
| Sep 30, 2024 | 46.21 Mn |
| Jun 30, 2024 | 36.71 Mn |
| Mar 31, 2024 | 35.06 Mn |
| Dec 31, 2023 | 62.64 Mn |
| Sep 30, 2023 | 70.78 Mn |
| Jun 30, 2023 | 48.71 Mn |
| Mar 31, 2023 | 36.42 Mn |
| Dec 31, 2022 | 62.67 Mn |
| Sep 30, 2022 | 46.37 Mn |
| Jun 30, 2022 | 35.83 Mn |
| Mar 31, 2022 | 29.49 Mn |
| Dec 31, 2021 | 55.73 Mn |
| Sep 30, 2021 | 39.37 Mn |